| Revenue growth | 23% YoY revenue growth to ₹6,813 crore in FY26. |
|---|---|
| Margins | EBITDA margins expanded 6.7% points to 26.8% due to mix. |
| Demand visibility | Strong visibility for CDMO; servicing 1/3rd of global HIV population. |
| Management confidence | Balanced confidence; shifting focus to high-growth CDMO and new modalities. |
Growth
FY26 revenue reached ₹6,813 crore, driven by a 38% surge in small molecule CDMO and affordable medicines growth.
Outlook
Guided 50% CDMO revenue share by 2030; ₹3,000 crore capex planned over the next two years.
Risks
Geopolitical disruptions affecting raw material logistics; high capex intensity may pressure near-term free cash flow.
Earnings Call filed with BSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,050.00
- Market cap
- ₹1,10,764 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 101.3×Sector 47.4×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs Other Announcement
Laurus Labs has been assigned an ESG score of 63 out of 100 for FY 2026 by NSE Sustainability Ratings and Analytics Limited.
Laurus Labs Employee Stock Options
Laurus Labs has allotted 62,635 equity shares to employees upon the exercise of vested stock options under its ESOP schemes.
Laurus Labs Merger & Restructuring
Laurus Labs announced the NCLT has issued an order regarding its Composite Scheme of Arrangement. The court directed notices be served for the upcoming September hearing.
Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Results Update
Laurus Labs reported Q1 FY27 revenue of ₹2,026 Crore and EBITDA of ₹644 Crore. The results show 29% year-on-year revenue growth.